Disease · MONDO_0006082

anal squamous cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anal squamous cell carcinoma. Diseases, record MONDO_0006082. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006082

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anal squamous cell carcinoma; Open Targets
Open Targets ID: MONDO_0006082; Open Targets
Other names: anal squamous cell cancer, anus squamous cell carcinoma, epidermoid anal carcinoma, epidermoid carcinoma of anus, epidermoid carcinoma of the anus, squamous cell anal carcinoma, squamous cell carcinoma - anus, squamous cell carcinoma of anus, squamous cell carcinoma of the anus; Open Targets
Disease Ontology: DOID:5525; Disease Ontology
NCI Thesaurus: C9161; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 6 of its 30 drugs, from ClinicalTrials.gov; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RETIFANLIMAB	CHEMBL4298037	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD274	Programmed cell death 1 ligand 1	4	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	2	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1493	Drugs and targets
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials26

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03013491	PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas	Phase 1/2	196	2025-06-17	Solid Tumor, Lymphoma	IPILIMUMAB, PACMILIMAB, VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT02797964	A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	Phase 1/2	107	2022-03-10	Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)	SRA-737	Its record names the disease	ClinicalTrials.gov
NCT01581840	Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus	Phase 1/2	45	2024-07-01	Epidermoid Carcinoma, Anus	FLUOROURACIL, MITOMYCIN, PANITUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02526953	Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients	Phase 3	314		Anus Neoplasms, Carcinoma, Squamous Cell, Anus Diseases, Neoplasms, Neoplasms, Squamous Cell, Carcinoma	CAPECITABINE, MITOMYCIN, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT06207981	Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA	Phase 3	310		Anal Cancer	CAPECITABINE, CISPLATIN, DOCETAXEL, FLUOROURACIL, MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT04166318	Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study	Phase 2	252		Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8	CAPECITABINE, FLUOROURACIL, MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT07555678	Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase	Phase 2	241		Anal Squamous Cell Cancer	NIVOLUMAB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04230759	Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group	Phase 2	180		Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II	DURVALUMAB, FLUOROURACIL, MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT01115790	A Phase 1 Study in Participants With Advanced Cancer	Phase 1	150		Advanced Cancer, Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Lung Squamous Cell Carcinoma Stage IV, Anal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung	PREXASERTIB	Its record names the disease	ClinicalTrials.gov
NCT04357873	Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations	Phase 2	112		Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer	PEMBROLIZUMAB, VORINOSTAT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 26

See all 26 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
CX-072 10 mg/kg (Part A and Part A2) vs CX-072 10 mg/kg (Part D): The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy	1 of 16	13 of 98	114	NCT03013491

Source Trial comparisons

Papers from its trials24

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31185328	RESULT	1	PubMed
30042063	RESULT	1	PubMed
19643599	RESULT	1	PubMed
42201333	DERIVED	1	PubMed
41544350	DERIVED	1	PubMed
41468684	DERIVED	1	PubMed
41202834	DERIVED	1	PubMed
40588522	DERIVED	1	PubMed
38547895	DERIVED	1	PubMed
37315583	DERIVED	1	PubMed

1 to 10 of 24

See all 24 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006082

GET https://conductscience.org/api/diseases/v1/MONDO_0006082/drugs?page=2

API reference For AI assistants